TG Therapeutics (NASDAQ:TGTX)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a report released on Tuesday. They currently have a $33.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s price objective indicates a potential upside of 243.75% from the company’s previous close.
Several other equities analysts have also recently issued reports on the stock. Zacks Investment Research cut shares of TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, January 13th. BidaskClub upgraded shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, January 11th. Raymond James Financial reiterated a “buy” rating on shares of TG Therapeutics in a research report on Tuesday, December 12th. B. Riley reiterated a “buy” rating and set a $21.50 price objective on shares of TG Therapeutics in a research report on Monday, December 11th. Finally, ValuEngine cut shares of TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, October 16th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the company’s stock. TG Therapeutics has an average rating of “Buy” and a consensus target price of $25.50.
Shares of TG Therapeutics (TGTX) traded up $0.05 during midday trading on Tuesday, reaching $9.60. 840,000 shares of the company’s stock traded hands, compared to its average volume of 1,597,100. TG Therapeutics has a 1 year low of $4.10 and a 1 year high of $15.35. The firm has a market cap of $672.96, a PE ratio of -4.97 and a beta of 1.30.
TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by ($0.05). TG Therapeutics had a negative net margin of 73,217.77% and a negative return on equity of 151.21%. The business had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.04 million. equities research analysts expect that TG Therapeutics will post -1.87 earnings per share for the current fiscal year.
In other news, CFO Sean A. Power sold 32,006 shares of the stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $8.50, for a total transaction of $272,051.00. Following the completion of the sale, the chief financial officer now directly owns 517,464 shares in the company, valued at $4,398,444. The transaction was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 16.70% of the company’s stock.
A number of large investors have recently bought and sold shares of the business. Legal & General Group Plc grew its holdings in TG Therapeutics by 14.9% in the second quarter. Legal & General Group Plc now owns 11,264 shares of the biopharmaceutical company’s stock worth $114,000 after purchasing an additional 1,463 shares during the period. California State Teachers Retirement System grew its holdings in TG Therapeutics by 1.9% in the second quarter. California State Teachers Retirement System now owns 85,935 shares of the biopharmaceutical company’s stock worth $864,000 after purchasing an additional 1,600 shares during the period. Nationwide Fund Advisors grew its holdings in TG Therapeutics by 24.2% in the second quarter. Nationwide Fund Advisors now owns 26,531 shares of the biopharmaceutical company’s stock worth $267,000 after purchasing an additional 5,167 shares during the period. Parametric Portfolio Associates LLC grew its holdings in TG Therapeutics by 7.5% in the second quarter. Parametric Portfolio Associates LLC now owns 85,612 shares of the biopharmaceutical company’s stock worth $860,000 after purchasing an additional 5,958 shares during the period. Finally, Voya Investment Management LLC grew its holdings in TG Therapeutics by 40.2% in the second quarter. Voya Investment Management LLC now owns 22,521 shares of the biopharmaceutical company’s stock worth $226,000 after purchasing an additional 6,463 shares during the period. Institutional investors and hedge funds own 50.41% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “TG Therapeutics (TGTX) Rating Reiterated by HC Wainwright” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international copyright & trademark laws. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/01/18/tg-therapeutics-tgtx-rating-reiterated-by-hc-wainwright.html.
About TG Therapeutics
TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.